Review of the use of pretest probability for molecular testing in non-small cell lung cancer and overview of new mutations that may affect clinical practice.
Review of the use of pretest probability for molecular testing in non-small cell lung cancer and overview of new mutations that may affect clinical practice.
复制标题
DOI：
10.1177/1758834017704329
复制
发表时间：
2017-06
影响因子：
4.9
通讯作者：
Leighl NB
中科院分区：
文献类型：
--
作者：
Martin P;Leighl NB
本文探讨了预测试概率在非小细胞肺癌 (NSCLC) 中的应用，以及其在 EGFR 测试中的应用如何帮助建立选择患者进行 EGFR 测试的临床指南。随着越来越多的分子异常被识别，并且可用于测试的组织通常有限，未来需要越来越多地考虑使用预测试概率来选择患者的研究和治疗。此外，我们还审查了可能影响临床实践的新突变。
This article considers the use of pretest probability in non-small cell lung cancer (NSCLC) and how its use in EGFR testing has helped establish clinical guidelines on selecting patients for EGFR testing. With an ever-increasing number of molecular abnormalities being identified and often limited tissue available for testing, the use of pretest probability will need to be increasingly considered in the future for selecting investigations and treatments in patients. In addition we review new mutations that have the potential to affect clinical practice.